Sign up to save your podcasts
Or
Share State of the Union: CAR T Cell Therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
State of the Union: CAR T Cell Therapy
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/state-of-the-union-car-t-cell-therapy/13658/
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 31-03-2023
Claim your CME credit at https://reachmd.com/programs/cme/state-of-the-union-car-t-cell-therapy/13658/
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
=